Grade @-@ neutropenia ( @ -LSB- @ % -RSB- for lenalidomide vs @ -LSB- @ % -RSB- for placebo ) , febrile neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , diarrhoea ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , pneumonia ( @ -LSB- @ % -RSB- vs five -LSB- @ % -RSB- ) , dyspnoea ( @ -LSB- @ % -RSB- vs nine -LSB- @ % -RSB- ) , asthenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and pulmonary embolism ( @ -LSB- @ % -RSB- vs seven -LSB- @ % -RSB- ) occurred more frequently in the lenalidomide group than in the placebo group .